Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(TEVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.

11/25/2021 | 12:00pm EST
  • Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future sales
  • Teva will receive an exclusive license to bring firibastat to its home market, Israel

PARIS, Nov. 25, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly targeting the brain to treat difficult-to-treat/resistant hypertension, has today announced the signing of an exclusive license agreement with Teva Israel Ltd. – a subsidiary of Teva Pharmaceutical Industries Ltd. to market firibastat in Israel.

A global pharmaceutical company founded and headquartered in Israel, Teva will receive exclusive marketing, selling and distribution rights for resistant and difficult-to-treat hypertension in its home market.

Quantum Genomics will receive payments of up to $11 M and 25% minimum up to 30% royalties on future firibastat sales.

"Teva is now one of the world’s largest pharmaceutical companies. Its expertise and reputation are beyond doubt, as shown by its incredible management of the Covid-19 vaccination campaign in Israel. We’re proud to be partnering one of the pharmaceutical industry’s biggest successes, which is sure to make firibastat a leading technology in its category. We’re already talking about extending this exclusive license to new territories where Teva operates," said Jean-Philippe Milon, CEO of Quantum Genomics.

"We are very pleased to collaborate with Quantum Genomics in order to tackle together a substantial unmet need and introduce firibastat an innovative treatment to our Israeli patients suffering from resistant and difficult-to-treat hypertension," said Yossi Ofek, CEO of Teva Israel Ltd. and Cluster Head of Israel, Ukraine, South Africa & MEA. "Teva Israel has a robust and wide medicine portfolio, which consists of hundreds of generic, specialty and OTC medicines supporting most of Israel's medical needs, firibastat is an important addition to our value proposition in the field of cardiovascular diseases."

About TEVA

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular drugs, based on the Brain Aminopeptidase A Inhibition (BAPAI) mechanism. It is the only company in the world to pursue this innovative approach directly targeting the brain, founded upon more than twenty years of research work by Paris-Descartes University and the INSERM/CNRS laboratory led by Dr. Catherine Llorens-Cortès at the Collège de France. Quantum Genomics thus aims to develop innovative treatments for complicated or even resistant hypertension (in approximately 30% of patients it is poorly controlled or treatment failure occurs), and heart failure (one in two patients diagnosed dies within five years).

Based in Paris and New York, the company is listed on the Euronext Growth market in Paris (FR0011648971 – ALQGC) and the US market OTCQX (symbol: QNNTF).

More information on www.quantum-genomics.com, our Twitter and LinkedIn accounts

Contacts

Quantum Genomics
contact@quantum-genomics.com
 
Edifice Communication (EUROPE)
Financial and Media Relations
quantum-genomics@edifice-communication.com
 
LifeSci (USA)
Mike Tattory
Media Relations
+1 (646) 751-4362 – mtattory@lifescipublicrelations.com

Primary Logo

Source: Quantum Genomics

2021 GlobeNewswire, Inc., source Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
QUANTUM GENOMICS -3.09% 4.08 Real-time Quote.-4.81%
TEVA PHARMACEUTICAL INDUSTRIES LIMITED -1.50% 8.51 Delayed Quote.6.24%
All news about TEVA PHARMACEUTICAL INDUSTRIES LIMITED
01/18Teva settles shareholder lawsuit over generic drug pricing for $420 mln
RE
01/18Teva settles shareholder lawsuit over generic drug pricing for $420 mln
RE
01/18Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Res..
BU
01/18IMMUNEERING CORP : Change in Directors or Principal Officers, Financial Statements and Exh..
AQ
01/18Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M...
AQ
01/06Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Mo..
AQ
01/04Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
BU
01/03Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President,áProject and Allian..
AQ
2021Thinking about buying stock in SuperCom, Teva Pharmaceutical, Future Fintech Group, Spr..
PR
2021ADRs End Mostly Higher; Teva Down on Opioid Verdict
DJ
More news
Analyst Recommendations on TEVA PHARMACEUTICAL INDUSTRIES LIMITED
More recommendations
Financials (USD)
Sales 2021 16 194 M - -
Net income 2021 954 M - -
Net Debt 2021 21 746 M - -
P/E ratio 2021 11,2x
Yield 2021 -
Capitalization 9 387 M 9 387 M -
EV / Sales 2021 1,92x
EV / Sales 2022 1,78x
Nbr of Employees 37 736
Free-Float -
Chart TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Duration : Period :
Teva Pharmaceutical Industries Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Last Close Price 8,51 $
Average target price 10,47 $
Spread / Average Target 23,0%
EPS Revisions
Managers and Directors
Kňre Schultz President, Chief Executive Officer & Director
Eli Kalif Chief Financial Officer & Executive Vice President
Sol J. Barer Chairman
Hafrun Fridriksdottir President-Global Generics Research & Development
Eric DrapÚ Executive Vice President-Global Operations
Sector and Competitors
1st jan.Capi. (M$)
TEVA PHARMACEUTICAL INDUSTRIES LIMITED6.24%9 387
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356